Q1 net loss $11.8M ($0.65/sh); Phase 2 DFS readout mid-2026; cash runway into Q4

Elicio Therapeutics, Inc.

2026-Q1 EPS reported -$0.65 vs consensus -$0.47 ▼ miss (-37.0%)

Q1 net loss $11.8M ($0.65/sh) vs $11.2M ($0.87/sh) YoY; R&D $6.8M, G&A $3.8M.
Cash $14.9M at Mar 31; raised $13M via ATM in Q1-Q2; expected runway into Q4 2026.
Phase 2 AMPLIFY-7P primary DFS analysis for ELI-002 7P in PDAC expected mid-2026; fewer events observed.
Company remains blinded; after DFS readout, plans End-of-Phase 2 FDA meeting for Phase 3 design.

item 2.02item 9.01

Source: SEC EDGAR

accession 0001601485-26-000041

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.